BCL2 and acute myeloid leukemia: The combination of the BCL-2 inhibitor venetoclax (VEN) with a hypomethylating agent (HMA) or low-dose Ara-C elicits complete remission/complete remission with incomplete hematologic recovery rates of >65%, is well tolerated by elderly AML patients [9, 10], and has been approved by the US Food and Drug Administration.